Target intelligence / Profile preview

Immunoglobulin kappa variable 2-14 (IGKV2-14)

Target
IGKV2-14
Molecular classification
Immunoglobulin variable region gene, Kappa light chain variable segment, Other (classified within "immunoglobulin gene segments," rather than protein families like receptors or enzymes)
01

Overview

Immunoglobulin kappa variable 2-14 is a variable (V) gene segment in the human immunoglobulin kappa locus, which encodes a portion of the variable domain of kappa light chains in antibodies. The kappa variable regions are critical for the diverse antigen-binding specificity of antibodies, accomplished through somatic recombination (joining V, J, and constant segments). IGKV2-14 is one member of a multigene family, and its usage in B cells contributes to the diversity of the antibody repertoire. Aberrant rearrangement or mutation of IGKV segments is associated with certain hematological malignancies but is not a therapeutic drug target by itself[2]. If structured information for antibody chains themselves, rather than functional proteins, is desired, note that these gene segments are not conventionally catalogued as "drug targets" in pharmacological databases. The clinical relevance is primarily in diagnostics (clonality analysis in hematology) and in antibody engineering[2].

Other names
IGKV2-14immunoglobulin kappa variable region 2-14IGK V2-14
02

Mechanism of action

Not applicable directly. As a gene segment, its principle "mechanism" is recombination to form the antigen-binding site of kappa chain antibodies, contributing to high antigen specificity

03

Biological functions

Antigen recognition (as part of the antibody molecule's variable domain)Immune response (crucial for adaptive immunity, enabling B cells to generate diverse antibodies that bind specific antigens)
04

Disease associations

Other: Dysregulation and somatic mutations in immunoglobulin variable genes (including kappa chains) have roles in lymphoid malignancies (e.g., leukemia, lymphoma)
05

Safety considerations

None specific or notable. As an endogenous immunoglobulin gene segment, safety issues only pertain to genetic abnormalities or clonal expansions in diseases such as lymphoma
06

Biomarkers

None specific. Clonal rearrangement of IGKV genes in B-cell malignancies can be biomarkers for disease monitoring in lymphoproliferative disorders

Beyond the preview

Go deeper on Immunoglobulin kappa variable 2-14 (IGKV2-14).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 2-14 (IGKV2-14).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call